Press releaseGlobe Newswire
Daxor
DXR · NASDAQ
$9.75−$0.09 (−0.91%)TodayMarket closed ·
Prev close $9.84
Latest news
- Press releaseGlobe Newswire
Daxor Announces Strong Commercial Interest and New Clinical Data at HFSA 2026
- Press releaseGlobe Newswire
Daxor to Showcase Blood Volume Analysis Platform at ASN Kidney Week 2026
- Press releaseGlobe Newswire
Daxor to Showcase Next-Gen Blood Volume Analyzer and New Clinical Data at HFSA 2026
- Press releaseGlobe Newswire
Daxor Corporation to Participate in the 10th Annual Lake Street Best Ideas Growth Conference
- Press releaseGlobe Newswire
Daxor Corporation CEO and President Michael Feldschuh Delivers 1st Half Corporate Update in Shareholder Letter
- Press releaseGlobe Newswire
Daxor Broadens Outpatient Footprint with Initiation of ezBVA Lab Diagnostic Services in Kansas
- Press releaseGlobe Newswire
Daxor Corporation Announces First-Time Exhibition at the 14th Annual Dysautonomia International Conference in The Woodlands, Texas
- Press releaseGlobe Newswire
Daxor Corporation Receives U.S. Patent for Breakthrough Remote Blood Volume Monitor
- Press releaseGlobe Newswire
Daxor Leverages MedAxiom CV Transforum Spring'26 to Accelerate Commercial Adoption of Blood Volume Analysis
- Press releaseGlobe Newswire
Daxor Expands Customer Footprint with New BVA Program at High-Volume Ohio Cardiology Center
- Press releaseGlobe Newswire
Daxor's Blood Volume Analysis Metric Validated as Uniquely Accurate Versus Capillary Leak Indexes in New Clinical Data Presented at SCCM 2026
- Press releaseGlobe Newswire
Daxor Corporation to Showcase Next-Generation Portable Blood Volume Analyzer at ACC.26; Highlighting Clinical Outcomes and Reduced Readmissions
- Press releaseGlobe Newswire
Daxor to Debut New Rapid, Portable Blood Volume Analyzer at SCCM 2026 Critical Care Congress
- Press releaseGlobe Newswire
Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders
- Press releaseGlobe Newswire
Daxor Scales Outpatient Presence; Launches BVA Diagnostic Program in Tennessee
- Press releaseGlobe Newswire
Daxor Corporation Announces Transition To Securities Exchange Act of 1934 Reporting Company, Reaffirming Focus on Core Blood Volume Analysis and Diagnostic Business
- Press releaseGlobe Newswire
Daxor Fuels Growth with Three New Facility Adoptions and Deployment of Next-Generation BVA Analyzer
- Press releaseGlobe Newswire
Daxor CEO Michael Feldschuh to Engage Investors at Exclusive Maxim Growth Summit
- Press releaseGlobe Newswire
Daxor's New BVA Technology To Be Showcased At MedAxiom CV Transforum Fall '25
- Press releaseGlobe Newswire
Daxor Unveils New FDA-Cleared BVA Analyzer Amid Strong Market Demand and Pivotal Clinical Data at HFSA
- Press releaseGlobe Newswire
Daxor Corporation Unveils Breakthrough Next-Gen BVA Analyzer at HFSA Annual Scientific Meeting
- Press releaseGlobe Newswire
Daxor's Blood Volume Analysis Validated for COVID and Sepsis Patients in New Peer-Reviewed Pilot Study Published in the Journal of Critical Care
- Press releaseGlobe Newswire
Daxor Corporation to Present at the H.C. Wainwright 27th Annual Global Investment Conference
- Press releaseGlobe Newswire
Daxor Corporation CEO and President Michael Feldschuh Delivers 1st Half Corporate Update in Shareholder Letter
- Press releaseGlobe Newswire
Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.